1 of 2
FILE - In this Monday, July 27, 2020 file photo, a nurse prepares a shot as a study of a possible COVID-19 vaccine, developed by the National Institutes of Health and Moderna Inc., gets underway in Binghamton, N.Y. On Thursday, Dec. 17, 2020, a panel of independent experts is meeting to discuss a vaccine made by Moderna. The panel's review for the Food and Drug Administration is the next-to-last step before the agency decides whether the shots can be used on an emergency basis. (AP Photo/Hans Pennink)
2 of 2
FILE - A man stands outside an entrance to a Moderna, Inc., building, Monday, May 18, 2020, in Cambridge, Mass. A second COVID-19 vaccine moved closer to joining the U.S. fight against the pandemic Thursday, Dec. 17, 2020 as government experts convened for a final public review of its safety and effectiveness. The shot from Moderna and the National Institutes of Health is urgently needed as the country continues to record ever-higher numbers of new cases, hospitalizations and deaths ahead of more holiday travel and family gatherings. FDA's OK is expected shortly after the all-day meeting concludes. (AP Photo/Bill Sikes, file)